223 related articles for article (PubMed ID: 25393793)
1. Phase II study of Amrubicin combined with carboplatin for thymic carcinoma and invasive thymoma: North Japan Lung Cancer group study 0803.
Inoue A; Sugawara S; Harada M; Kobayashi K; Kozuki T; Kuyama S; Maemondo M; Asahina H; Hisamoto A; Nakagawa T; Hotta K; Nukiwa T
J Thorac Oncol; 2014 Dec; 9(12):1805-9. PubMed ID: 25393793
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of amrubicin combined with carboplatin for refractory relapsed small-cell lung cancer: North Japan Lung Cancer Group Trial 0802.
Kawashima Y; Inoue A; Sugawara S; Oizumi S; Maemondo M; Okudera K; Suzuki T; Usui K; Harada M; Morikawa N; Hasegawa Y; Saito R; Ishimoto O; Sakakibara T; Asahina H; Nukiwa T
Respir Investig; 2014 May; 52(3):190-4. PubMed ID: 24853020
[TBL] [Abstract][Full Text] [Related]
3. Phase II study of S-1 in patients with previously-treated invasive thymoma and thymic carcinoma: North Japan lung cancer study group trial 1203.
Tsukita Y; Inoue A; Sugawara S; Kuyama S; Nakagawa T; Harada D; Tanaka H; Watanabe K; Mori Y; Harada T; Hino T; Fujii M; Ichinose M
Lung Cancer; 2020 Jan; 139():89-93. PubMed ID: 31751805
[TBL] [Abstract][Full Text] [Related]
4. Amrubicin as second-line and beyond treatment for platinum-refractory advanced thymic carcinoma.
Hirai F; Seto T; Yamanaka T; Toyozawa R; Inamasu E; Kojo M; Toyokawa G; Morodomi Y; Shiraishi Y; Takenaka T; Yamaguchi M; Takenoyama M; Ichinose Y
Jpn J Clin Oncol; 2013 Oct; 43(10):1018-22. PubMed ID: 23917962
[TBL] [Abstract][Full Text] [Related]
5. A multicenter phase II study of carboplatin and paclitaxel for advanced thymic carcinoma: WJOG4207L.
Hirai F; Yamanaka T; Taguchi K; Daga H; Ono A; Tanaka K; Kogure Y; Shimizu J; Kimura T; Fukuoka J; Iwamoto Y; Sasaki H; Takeda K; Seto T; Ichinose Y; Nakagawa K; Nakanishi Y;
Ann Oncol; 2015 Feb; 26(2):363-8. PubMed ID: 25403584
[TBL] [Abstract][Full Text] [Related]
6. Randomized phase II trial comparing amrubicin with re-challenge of platinum doublet in patients with sensitive-relapsed small-cell lung cancer: North Japan Lung Cancer Study Group trial 0702.
Inoue A; Sugawara S; Maemondo M; Mori Y; Oizumi S; Harada M; Taima K; Morikawa N; Ishida T; Kinoshita I; Watanabe H; Suzuki T; Nakagawa T; Saito R; Nukiwa T
Lung Cancer; 2015 Jul; 89(1):61-5. PubMed ID: 26004087
[TBL] [Abstract][Full Text] [Related]
7. Phase II trial of single agent amrubicin in patients with previously treated advanced thymic malignancies.
Hellyer JA; Gubens MA; Cunanan KM; Padda SK; Burns M; Spittler AJ; Riess JW; San Pedro-Salcedo M; Ramchandran KJ; Neal JW; Wakelee HA; Loehrer PJ
Lung Cancer; 2019 Nov; 137():71-75. PubMed ID: 31557562
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of carboplatin and paclitaxel in advanced thymoma and thymic carcinoma.
Lemma GL; Lee JW; Aisner SC; Langer CJ; Tester WJ; Johnson DH; Loehrer PJ
J Clin Oncol; 2011 May; 29(15):2060-5. PubMed ID: 21502559
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of chemotherapy with carboplatin and paclitaxel for unresectable thymic carcinoma.
Igawa S; Murakami H; Takahashi T; Nakamura Y; Tsuya A; Naito T; Kaira K; Ono A; Shukuya T; Tamiya A; Endo M; Yamamoto N
Lung Cancer; 2010 Feb; 67(2):194-7. PubMed ID: 19409644
[TBL] [Abstract][Full Text] [Related]
10. A phase II study of amrubicin combined with carboplatin for elderly patients with small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0405.
Inoue A; Ishimoto O; Fukumoto S; Usui K; Suzuki T; Yokouchi H; Maemondo M; Kanbe M; Ogura S; Harada T; Oizumi S; Harada M; Sugawara S; Fukuhara T; Nukiwa T
Ann Oncol; 2010 Apr; 21(4):800-803. PubMed ID: 19825887
[TBL] [Abstract][Full Text] [Related]
11. Combined etoposide, ifosfamide, and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma: an intergroup trial.
Loehrer PJ; Jiroutek M; Aisner S; Aisner J; Green M; Thomas CR; Livingston R; Johnson DH
Cancer; 2001 Jun; 91(11):2010-5. PubMed ID: 11391579
[TBL] [Abstract][Full Text] [Related]
12. Intensive chemotherapy with cisplatin, doxorubicin, cyclophosphamide, etoposide and granulocyte colony-stimulating factor for advanced thymoma or thymic cancer: preliminary results.
Oshita F; Kasai T; Kurata T; Fukuda M; Yamamoto N; Ohe Y; Tamura T; Eguchi K; Shinkai T; Saijo N
Jpn J Clin Oncol; 1995 Oct; 25(5):208-12. PubMed ID: 7474409
[TBL] [Abstract][Full Text] [Related]
13. Phase II trial of amrubicin and carboplatin in patients with sensitive or refractory relapsed small-cell lung cancer.
Hirose T; Nakashima M; Shirai T; Kusumoto S; Sugiyama T; Yamaoka T; Okuda K; Ohnishi T; Ohmori T; Adachi M
Lung Cancer; 2011 Sep; 73(3):345-50. PubMed ID: 21277039
[TBL] [Abstract][Full Text] [Related]
14. Results of S-1-based chemotherapy for platinum (and antrathycline)-refractory advanced thymic carcinoma.
Hirai F; Seto T; Inamasu E; Toyokawa G; Yoshida T; Nosaki K; Takenaka T; Yamaguchi M; Takenoyama M; Ichinose Y
Anticancer Res; 2014 Oct; 34(10):5743-7. PubMed ID: 25275083
[TBL] [Abstract][Full Text] [Related]
15. A phase II study of amrubicin and carboplatin for previously untreated patients with extensive-disease small cell lung cancer.
Ikeda T; Fukuda M; Nakamura Y; Kinoshita A; Senju H; Nakano H; Kitazaki T; Ogawara D; Taniguchi H; Motoshima K; Yamaguchi H; Nakatomi K; Shimada M; Nagashima S; Tsukamoto K; Kohno S;
Cancer Chemother Pharmacol; 2014 Sep; 74(3):497-502. PubMed ID: 25034978
[TBL] [Abstract][Full Text] [Related]
16. Combination chemotherapy with carboplatin and paclitaxel for advanced thymic cancer.
Furugen M; Sekine I; Tsuta K; Horinouchi H; Nokihara H; Yamamoto N; Kubota K; Tamura T
Jpn J Clin Oncol; 2011 Aug; 41(8):1013-6. PubMed ID: 21742653
[TBL] [Abstract][Full Text] [Related]
17. Study Design and Rationale for Marble Study: A Phase II Trial of Atezolizumab (MPDL3280A) Plus Carboplatin and Paclitaxel in Patients With Advanced or Recurrent Thymic Carcinoma (JTD2101).
Asao T; Shukuya T; Mimori T; Goto Y; Tanaka H; Takayama K; Tsubata Y; Tachihara M; Suzuki T; Kaira K; Ko R; Zenke Y; Akamatsu H; Tanizaki J; Ikeda S; Sugawara S; Mizutani H; Mori K; Takahashi K
Clin Lung Cancer; 2023 Nov; 24(7):e247-e253. PubMed ID: 37316381
[TBL] [Abstract][Full Text] [Related]
18. RELEVENT Trial: Phase II Trial of Ramucirumab, Carboplatin, and Paclitaxel in Previously Untreated Thymic Carcinoma/B3 Thymoma With Area of Carcinoma.
Imbimbo M; Vitali M; Fabbri A; Ottaviano M; Pasello G; Petrini I; Palmieri G; Berardi R; Zucali P; Ganzinelli M; Marabese M; Broggini M; Marino M; Trama A; Rulli E; Hollander L; Pruneri G; Torri V; Garassino MC
Clin Lung Cancer; 2018 Sep; 19(5):e811-e814. PubMed ID: 30033090
[TBL] [Abstract][Full Text] [Related]
19. A phase I study of amrubicin and carboplatin for previously untreated patients with extensive-disease small cell lung cancer.
Fukuda M; Nakamura Y; Kasai T; Nagashima S; Nakatomi K; Doi S; Nakano H; Takatani H; Fukuda M; Kinoshita A; Soda H; Tsukamoto K; Oka M; Kohno S;
J Thorac Oncol; 2009 Jun; 4(6):741-5. PubMed ID: 19404211
[TBL] [Abstract][Full Text] [Related]
20. A randomized phase III study of single-agent amrubicin vs. carboplatin/etoposide in elderly patients with extensive-disease small-cell lung cancer.
Sekine I; Okamoto H; Horai T; Nakagawa K; Ohmatsu H; Yokoyama A; Katakami N; Shibuya M; Saijo N; Fukuoka M
Clin Lung Cancer; 2014 Mar; 15(2):96-102. PubMed ID: 24361248
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]